Study On Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE) (SUCRE)
maanantai 14. huhtikuuta 2014 päivittänyt: Pfizer
Study on Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE)
The overall goal of this study will be to assess and monitor the adherence to and effectiveness of the new prescribing guidelines for cabergoline.
Specific objectives will be to assess: 1. The indication for use of cabergoline (Parkinson, hyperprolactinemia, other) 2. Prior treatment strategies in patients who start cabergoline treatment for Parkinson's Disease 3. The percentage of cabergoline users who are prescribed doses above 3 mg per day 4. Whether cabergoline users are monitored by echocardiography prior and during treatment. 5. The incidence and prevalence of valvular fibrosis
Tutkimuksen yleiskatsaus
Yksityiskohtainen kuvaus
does not involve random selection
Opintotyyppi
Havainnollistava
Ilmoittautuminen (Todellinen)
22014
Osallistumiskriteerit
Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.
Kelpoisuusvaatimukset
Opintokelpoiset iät
- Lapsi
- Aikuinen
- Vanhempi Aikuinen
Hyväksyy terveitä vapaaehtoisia
Ei
Sukupuolet, jotka voivat opiskella
Kaikki
Näytteenottomenetelmä
Ei-todennäköisyysnäyte
Tutkimusväestö
Cohort of patients, who are treated with cabergoline during the study period.
This cohort will be divided in new users and prevalent users based on when cabergoline was started.
New (incident) users will be all persons who have a first prescription for cabergoline after the date that the change in SPC was made.
Prevalent users will be all cohort members who received a cabergoline prescription during the study period but who had also been using cabergoline prior to the change in SPC.
Kuvaus
Inclusion Criteria:
- Treated with cabergoline during the study period (January 1st, 2006 and will end on July 1st 2012) and identified in one of 6 databases: The Health Information Network, Health Search Database, Integrated Primary Care Information database, PHARMO, Aarhus hospital databases, and the Universitaet Bremen - Bremen Institute for Prevention
Exclusion Criteria:
- Patients with eligibility dates that start after July 1st 2007 (meaning that they would have less than one year of valid data before publication of the results of the EMEA review), will be excluded as well as patients whose eligibility ends before July 1st 2008 (date of SmPC changes).
Opintosuunnitelma
Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
Kohortit ja interventiot
Ryhmä/Kohortti |
Interventio / Hoito |
|---|---|
|
Cabergoline users
cohort of patients, who are treated with cabergoline during the study period ( from January 1st, 2006 to July 1st 2012)
|
non interventional study - usage as per usual care
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Number of Cabergoline Prescriptions by Database and Indication: Year 1
Aikaikkuna: Year 1 (Year 2006)
|
Cabergoline prescriptions were stratified by indications per year.
Indications were coded using Anatomical Therapeutic Code (ATC) which included G02CB03 for prolactin reduction indication and N04BC06 for neurological indication.
|
Year 1 (Year 2006)
|
|
Number of Cabergoline Prescriptions by Database and Indication: Year 2
Aikaikkuna: Year 2 (Year 2007)
|
Cabergoline prescriptions were stratified by indications per year.
Indications were coded using Anatomical Therapeutic Code (ATC) which included G02CB03 for prolactin reduction indication and N04BC06 for neurological indication.
|
Year 2 (Year 2007)
|
|
Number of Cabergoline Prescriptions by Database and Indication: Year 3
Aikaikkuna: Year 3 (Year 2008)
|
Cabergoline prescriptions were stratified by indications per year.
Indications were coded using Anatomical Therapeutic Code (ATC) which included G02CB03 for prolactin reduction indication and N04BC06 for neurological indication.
|
Year 3 (Year 2008)
|
|
Number of Cabergoline Prescriptions by Database and Indication: Year 4
Aikaikkuna: Year 4 (Year 2009)
|
Cabergoline prescriptions were stratified by indications per year.
Indications were coded using Anatomical Therapeutic Code (ATC) which included G02CB03 for prolactin reduction indication and N04BC06 for neurological indication.
|
Year 4 (Year 2009)
|
|
Number of Cabergoline Prescriptions by Database and Indication: Year 5
Aikaikkuna: Year 5 (Year 2010)
|
Cabergoline prescriptions were stratified by indications per year.
Indications were coded using Anatomical Therapeutic Code (ATC) which included G02CB03 for prolactin reduction indication and N04BC06 for neurological indication.
|
Year 5 (Year 2010)
|
|
Number of Cabergoline Prescriptions by Database and Indication: Year 6
Aikaikkuna: Year 6 (Year 2011)
|
Cabergoline prescriptions were stratified by indications per year.
Indications were coded using Anatomical Therapeutic Code (ATC) which included G02CB03 for prolactin reduction indication and N04BC06 for neurological indication.
|
Year 6 (Year 2011)
|
|
Percentage of Second-line Prescriptions of Cabergoline for Parkinson's Disease Indications: Year 1
Aikaikkuna: Year 1 (Year 2006)
|
Changes to the Summary of Product Characteristics (SPC) included that the cabergoline should be used for Parkinson's disease only in participants who had already taken or cannot take other treatments, which was as second line therapy.
Second-line use restriction did not apply to the hyperprolactinemia indication, for which cabergoline was considered a first-time therapy.
Percentage of second-line prescriptions of a total number of prescriptions for cabergoline during a respective year for the neurological indication was reported.
|
Year 1 (Year 2006)
|
|
Percentage of Second-line Prescriptions of Cabergoline for Parkinson's Disease Indications: Year 2
Aikaikkuna: Year 2 (Year 2007)
|
Changes to the Summary of Product Characteristics (SPC) included that the cabergoline should be used for Parkinson's disease only in participants who had already taken or cannot take other treatments, which was as second line therapy.
Second-line use restriction did not apply to the hyperprolactinemia indication, for which cabergoline was considered a first-time therapy.
Percentage of second-line prescriptions of a total number of prescriptions for cabergoline during a respective year for the neurological indication was reported.
|
Year 2 (Year 2007)
|
|
Percentage of Second-line Prescriptions of Cabergoline for Parkinson's Disease Indications: Year 3
Aikaikkuna: Year 3 (Year 2008)
|
Changes to the Summary of Product Characteristics (SPC) included that the cabergoline should be used for Parkinson's disease only in participants who had already taken or cannot take other treatments, which was as second line therapy.
Second-line use restriction did not apply to the hyperprolactinemia indication, for which cabergoline was considered a first-time therapy.
Percentage of second-line prescriptions of a total number of prescriptions for cabergoline during a respective year for the neurological indication was reported.
|
Year 3 (Year 2008)
|
|
Percentage of Second-line Prescriptions of Cabergoline for Parkinson's Disease Indications: Year 4
Aikaikkuna: Year 4 (Year 2009)
|
Changes to the Summary of Product Characteristics (SPC) included that the cabergoline should be used for Parkinson's disease only in participants who had already taken or cannot take other treatments, which was as second line therapy.
Second-line use restriction did not apply to the hyperprolactinemia indication, for which cabergoline was considered a first-time therapy.
Percentage of second-line prescriptions of a total number of prescriptions for cabergoline during a respective year for the neurological indication was reported.
|
Year 4 (Year 2009)
|
|
Percentage of Second-line Prescriptions of Cabergoline for Parkinson's Disease Indications: Year 5
Aikaikkuna: Year 5 (Year 2010)
|
Changes to the Summary of Product Characteristics (SPC) included that the cabergoline should be used for Parkinson's disease only in participants who had already taken or cannot take other treatments, which was as second line therapy.
Second-line use restriction did not apply to the hyperprolactinemia indication, for which cabergoline was considered a first-time therapy.
Percentage of second-line prescriptions of a total number of prescriptions for cabergoline during a respective year for the neurological indication was reported.
|
Year 5 (Year 2010)
|
|
Percentage of Second-line Prescriptions of Cabergoline for Parkinson's Disease Indications: Year 6
Aikaikkuna: Year 6 (Year 2011)
|
Changes to the Summary of Product Characteristics (SPC) in April 2007 included that the cabergoline should be used for Parkinson's disease only in participants who have already taken or cannot take other treatments, that is as second line therapy.
Second-line use restriction did not apply to the hyperprolactinemia indication, for which cabergoline is considered a first-time therapy.
Percentage of second-line prescriptions of a total number of prescriptions for cabergoline during a respective year for the neurological indication was reported.
|
Year 6 (Year 2011)
|
|
Percentage of Cabergoline Prescriptions for Dosages Greater Than 3 Milligram (mg) Per Day: Year 1
Aikaikkuna: Year 1 (Year 2006)
|
The Committee for Medicinal Products for Human Use (CHMP) recommended that the prescribing information for cabergoline should be updated to include: a reduction of the maximum recommended dose to 3 mg per day.
To evaluate compliance with the new prescription guidelines, it was assessed whether the dose exceeded 3 mg per day during the study period.
|
Year 1 (Year 2006)
|
|
Percentage of Cabergoline Prescriptions for Dosages Greater Than 3 Milligram (mg) Per Day: Year 2
Aikaikkuna: Year 2 (Year 2007)
|
The Committee for Medicinal Products for Human Use (CHMP) recommended that the prescribing information for cabergoline should be updated to include: a reduction of the maximum recommended dose to 3 mg per day.
To evaluate compliance with the new prescription guidelines, it was assessed whether the dose exceeded 3 mg per day during the study period.
|
Year 2 (Year 2007)
|
|
Percentage of Cabergoline Prescriptions for Dosages Greater Than 3 Milligram (mg) Per Day: Year 3
Aikaikkuna: Year 3 (Year 2008)
|
The Committee for Medicinal Products for Human Use (CHMP) recommended that the prescribing information for cabergoline should be updated to include: a reduction of the maximum recommended dose to 3 mg per day.
To evaluate compliance with the new prescription guidelines, it was assessed whether the dose exceeded 3 mg per day during the study period.
|
Year 3 (Year 2008)
|
|
Percentage of Cabergoline Prescriptions for Dosages Greater Than 3 Milligram (mg) Per Day: Year 4
Aikaikkuna: Year 4 (Year 2009)
|
The Committee for Medicinal Products for Human Use (CHMP) recommended that the prescribing information for cabergoline should be updated to include: a reduction of the maximum recommended dose to 3 mg per day.
To evaluate compliance with the new prescription guidelines, it was assessed whether the dose exceeded 3 mg per day during the study period.
|
Year 4 (Year 2009)
|
|
Percentage of Cabergoline Prescriptions for Dosages Greater Than 3 Milligram (mg) Per Day: Year 5
Aikaikkuna: Year 5 (Year 2010)
|
The Committee for Medicinal Products for Human Use (CHMP) recommended that the prescribing information for cabergoline should be updated to include: a reduction of the maximum recommended dose to 3 mg per day.
To evaluate compliance with the new prescription guidelines, it was assessed whether the dose exceeded 3 mg per day during the study period.
|
Year 5 (Year 2010)
|
|
Percentage of Cabergoline Prescriptions for Dosages Greater Than 3 Milligram (mg) Per Day: Year 6
Aikaikkuna: Year 6 (Year 2011)
|
The Committee for Medicinal Products for Human Use (CHMP) recommended that the prescribing information for cabergoline should be updated to include: a reduction of the maximum recommended dose to 3 mg per day.
To evaluate compliance with the new prescription guidelines, it was assessed whether the dose exceeded 3 mg per day during the study period.
|
Year 6 (Year 2011)
|
|
Total Number of Echocardiography Examinations in Cabergoline Users
Aikaikkuna: Baseline (Week 1) up to Week 339
|
The CHMP recommended that the prescribing information for cabergoline should be updated to include: a warning stating that participant must be monitored for signs of cardiac valve fibrosis with echocardiography before treatment is started and regularly (every 6 months) during treatment.
To evaluate effectiveness with the new prescription guidelines, it was assessed whether cabergoline users were monitored by echocardiography.
|
Baseline (Week 1) up to Week 339
|
|
Incidence of Valvular Fibrosis
Aikaikkuna: Baseline (Week 1) up to Week 339
|
Incidence of valvular fibrosis was calculated as number of participants with documented valvulopathy during cabergoline treatment and absence of any valve damage at baseline divided by number of participants without any valve damage at baseline and at least 1 additional echocardiography examination during follow-up while on cabergoline treatment.
Percentage of participants with valvular fibrosis are reported.
|
Baseline (Week 1) up to Week 339
|
|
Prevalence of Valvular Fibrosis
Aikaikkuna: Baseline (Week 1) up to Week 339
|
Prevalence of valvular fibrosis was calculated as number of participants with documented valvulopathy during cabergoline treatment divided by number of participants with at least 1 echocardiography examination.
Percentage of participants with valvular fibrosis are reported.
|
Baseline (Week 1) up to Week 339
|
Yhteistyökumppanit ja tutkijat
Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.
Sponsori
Julkaisuja ja hyödyllisiä linkkejä
Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.
Hyödyllisiä linkkejä
Opintojen ennätyspäivät
Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan julkisella verkkosivustolla.
Opi tärkeimmät päivämäärät
Opiskelun aloitus
Maanantai 1. marraskuuta 2010
Ensisijainen valmistuminen (Todellinen)
Perjantai 1. helmikuuta 2013
Opintojen valmistuminen (Todellinen)
Perjantai 1. helmikuuta 2013
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Torstai 9. joulukuuta 2010
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Tiistai 4. tammikuuta 2011
Ensimmäinen Lähetetty (Arvio)
Keskiviikko 5. tammikuuta 2011
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Arvio)
Perjantai 2. toukokuuta 2014
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Maanantai 14. huhtikuuta 2014
Viimeksi vahvistettu
Lauantai 1. helmikuuta 2014
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
- Aivojen sairaudet
- Keskushermoston sairaudet
- Hermoston sairaudet
- Endokriinisen järjestelmän sairaudet
- Parkinsonin häiriöt
- Basal ganglia -taudit
- Liikkumishäiriöt
- Synukleinopatiat
- Neurodegeneratiiviset sairaudet
- Hypotalamuksen sairaudet
- Hyperpituitarismi
- Aivolisäkkeen sairaudet
- Parkinsonin tauti
- Hyperprolaktinemia
Muut tutkimustunnusnumerot
- A7231030
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .